We wanted to bring to your attention some lesser known topics that you might find useful in your development strategy. Over the past few months, our consulting team has embedded deeply with several MedTech companies, uncovering a few hidden, costly pitfalls in the early-stage regulatory pipeline. Feel free to unsubscribe below if this content is not relevant.

Every researcher or sponsor developing a clinical trial understands that informed consent is one of the bedrock principles of ethical research.

Modern informed consent requirements, along with Institutional Review Board oversight, were shaped in part by public response to unethical research practices of the past. These safeguards exist to help protect transparency, patient autonomy, and public trust.

But some emergency medical research creates a difficult challenge.

In trials involving severe trauma, cardiac arrest, stroke, or other critical conditions, patients may be too sick or injured to provide consent. In many cases, there may also be no practical way to reach a legally authorized representative before treatment must begin.

That is where Exception From Informed Consent, commonly called EFIC, may apply.

EFIC is an FDA-regulated pathway that allows certain emergency research studies to proceed without prospective informed consent, but only when strict requirements are met. These studies are designed for situations where the research may involve a life-threatening condition, existing treatments may be unproven or unsatisfactory, and the treatment window is too short to obtain consent before intervention.

Importantly, EFIC is not a shortcut around patient protections.

Before an EFIC study can begin, the sponsor must demonstrate that obtaining informed consent is not feasible because of the emergency nature of the condition and the limited treatment window. The study must also undergo appropriate FDA and IRB review.

In addition, EFIC studies require extensive community consultation and public disclosure before the study begins. This means the affected community must be informed about the research, the potential risks and benefits must be explained, feedback must be gathered, and opportunities for questions or concerns must be provided.

Public disclosure is also required after the study is completed.

For sponsors, these additional requirements can be substantial. They may include protocol development, FDA communications, coordination with a central IRB, community engagement planning, public-facing study materials, and ongoing safety review.

But these requirements serve an important purpose.

They help balance the urgent need for emergency research with the ethical responsibility to protect patient rights, maintain transparency, and preserve public trust.

At Third Eye Associates, we support sponsors developing complex clinical research programs, including studies that may require EFIC planning, FDA interaction, IRB coordination, and ongoing trial oversight.